Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	Oliena Studio Stroke and language recovery: 9000+ videos Español • Italiano • Sardu • English | PDF+

Lung Cancer

Free Subscription Articles published in JAMA Oncol Retrieve available abstracts of 27 articles: HTML format Text format

Single Articles

May 2019
1. GIRI S, Huntington SF
   Changes to Model Assumptions of the Cost-effectiveness of Durvalumab Therapy for Non-Small Cell Lung Cancer.
   JAMA Oncol. 2019 May 16. pii: 2733792. doi: 10.1001/jamaoncol.2019.1088.
   PubMed     Text format    
   
   
   
2. CRISS SD, Mooradian MJ, Kong CY
   Changes to Model Assumptions of the Cost-effectiveness of Durvalumab Therapy for Non-Small Cell Lung Cancer-In Reply.
   JAMA Oncol. 2019 May 16. pii: 2733793. doi: 10.1001/jamaoncol.2019.1100.
   PubMed     Text format    
   
   
   April 2019
3. BERNER F, Bomze D, Diem S, Ali OH, et al
   Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer.
   JAMA Oncol. 2019 Apr 25. pii: 2731134. doi: 10.1001/jamaoncol.2019.0402.
   PubMed     Text format     Abstract available
   
   
   March 2019
4. MOR V, Wagner TH, Levy C, Ersek M, et al
   Association of Expanded VA Hospice Care With Aggressive Care and Cost for Veterans With Advanced Lung Cancer.
   JAMA Oncol. 2019 Mar 28. pii: 2729064. doi: 10.1001/jamaoncol.2019.0081.
   PubMed     Text format     Abstract available
   
   
   
5. SUN A, Hu C, Wong SJ, Gore E, et al
   Prophylactic Cranial Irradiation vs Observation in Patients With Locally Advanced Non-Small Cell Lung Cancer: A Long-term Update of the NRG Oncology/RTOG 0214 Phase 3 Randomized Clinical Trial.
   JAMA Oncol. 2019 Mar 14. pii: 2728245. doi: 10.1001/jamaoncol.2018.7220.
   PubMed     Text format     Abstract available
   
   
   February 2019
6. WANG Z, Duan J, Cai S, Han M, et al
   Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel.
   JAMA Oncol. 2019 Feb 28. pii: 2726029. doi: 10.1001/jamaoncol.2018.7098.
   PubMed     Text format     Abstract available
   
   
   
7. PALMA DA, Nguyen TK, Louie AV, Malthaner R, et al
   Measuring the Integration of Stereotactic Ablative Radiotherapy Plus Surgery for Early-Stage Non-Small Cell Lung Cancer: A Phase 2 Clinical Trial.
   JAMA Oncol. 2019 Feb 21. pii: 2725402. doi: 10.1001/jamaoncol.2018.6993.
   PubMed     Text format     Abstract available
   
   
   December 2018
8. TOI Y, Sugawara S, Sugisaka J, Ono H, et al
   Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
   JAMA Oncol. 2018 Dec 27. pii: 2718925. doi: 10.1001/jamaoncol.2018.5860.
   PubMed     Text format     Abstract available
   
   
   
9. CRISS SD, Mooradian MJ, Sheehan DF, Zubiri L, et al
   Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy vs No Consolidation Therapy After Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer in the Context of the US Health Care System.
   JAMA Oncol. 2018 Dec 13. pii: 2718006. doi: 10.1001/jamaoncol.2018.5449.
   PubMed     Text format     Abstract available
   
   
   
10. SALEM A, Mistry H, Hatton M, Locke I, et al
    Association of Chemoradiotherapy With Outcomes Among Patients With Stage I to II vs Stage III Small Cell Lung Cancer: Secondary Analysis of a Randomized Clinical Trial.
    JAMA Oncol. 2018 Dec 6:e185335. doi: 10.1001/jamaoncol.2018.5335.
    PubMed     Text format     Abstract available
    
    
    
11. WEST HJ
    Moving Beyond Limited and Extensive Staging of Small Cell Lung Cancer.
    JAMA Oncol. 2018 Dec 6. pii: 2717231. doi: 10.1001/jamaoncol.2018.5187.
    PubMed     Text format    
    
    
    November 2018
12. CHEN XZ
    Anlotinib for Refractory Advanced Non-Small Cell Lung Cancer in China.
    JAMA Oncol. 2018 Nov 29. pii: 2716809. doi: 10.1001/jamaoncol.2018.5526.
    PubMed     Text format    
    
    
    
13. SLOAN L, Romo CG, Hales RK
    Hemifacial Hyperhidrosis in a Patient With an Apical Non-Small Cell Lung Cancer.
    JAMA Oncol. 2018 Nov 15. pii: 2713851. doi: 10.1001/jamaoncol.2018.4597.
    PubMed     Text format    
    
    
    October 2018
14. EZE C, Kasmann L, Manapov F
    Redefining the Role of Prophylactic Cranial Irradiation in the Modern Era of Active Surveillance in Small Cell Lung Cancer.
    JAMA Oncol. 2018 Oct 25. pii: 2707226. doi: 10.1001/jamaoncol.2018.4833.
    PubMed     Text format    
    
    
    
15. GYAWALI B, West HJ
    Plasma vs Tissue Next-Generation Sequencing in Non-Small Cell Lung Cancer-Either, Both, or Neither?
    JAMA Oncol. 2018 Oct 11. pii: 2705603. doi: 10.1001/jamaoncol.2018.4304.
    PubMed     Text format    
    
    
    
16. AGGARWAL C, Thompson JC, Black TA, Katz SI, et al
    Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung Cancer.
    JAMA Oncol. 2018 Oct 11. pii: 2705609. doi: 10.1001/jamaoncol.2018.4305.
    PubMed     Text format     Abstract available
    
    
    
17. BOOZALIS E, Kwatra SG, Marrone KA
    Bilateral Lower Extremity Skin Eruptions in an HIV-Positive Man Receiving Pembrolizumab Monotherapy for Non-Small Cell Lung Cancer.
    JAMA Oncol. 2018 Oct 4. pii: 2704206. doi: 10.1001/jamaoncol.2018.4485.
    PubMed     Text format    
    
    
    September 2018
18. TUMINELLO S, Schwartz RM, Liu B, Mhango G, et al
    Opioid Use After Open Resection or Video-Assisted Thoracoscopic Surgery for Early-Stage Lung Cancer.
    JAMA Oncol. 2018 Sep 24. pii: 2703444. doi: 10.1001/jamaoncol.2018.4387.
    PubMed     Text format    
    
    
    
19. FERRARA R, Mezquita L, Texier M, Lahmar J, et al
    Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy.
    JAMA Oncol. 2018 Sep 6. pii: 2698845. doi: 10.1001/jamaoncol.2018.3676.
    PubMed     Text format     Abstract available
    
    
    August 2018
20. GRIDELLI C, de Castro Carpeno J, Dingemans AC, Griesinger F, et al
    Safety and Efficacy of Bevacizumab Plus Standard-of-Care Treatment Beyond Disease Progression in Patients With Advanced Non-Small Cell Lung Cancer: The AvaALL Randomized Clinical Trial.
    JAMA Oncol. 2018 Aug 30:e183486. doi: 10.1001/jamaoncol.2018.3486.
    PubMed     Text format     Abstract available
    
    
    
21. HAN B, Li K, Wang Q, Zhang L, et al
    Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial.
    JAMA Oncol. 2018 Aug 9. pii: 2696341. doi: 10.1001/jamaoncol.2018.3039.
    PubMed     Text format     Abstract available
    
    
    
22. ALCORN SR, Miller DB, Hales RK
    Underutilization of Combined-Modality Therapy in Limited-Stage Small Cell Lung Cancer.
    JAMA Oncol. 2018 Aug 2. pii: 2694876. doi: 10.1001/jamaoncol.2018.3261.
    PubMed     Text format    
    
    
    
23. PASQUINELLI MM, Kovitz KL, Koshy M, Menchaca MG, et al
    Outcomes From a Minority-Based Lung Cancer Screening Program vs the National Lung Screening Trial.
    JAMA Oncol. 2018 Aug 2. pii: 2694875. doi: 10.1001/jamaoncol.2018.2823.
    PubMed     Text format    
    
    
    
24. CHUN SG, Pezzi TA, Schwartz DL
    Underutilization of Combined-Modality Therapy in Limited-Stage Small Cell Lung Cancer-Reply.
    JAMA Oncol. 2018 Aug 2. pii: 2694877. doi: 10.1001/jamaoncol.2018.3292.
    PubMed     Text format    
    
    
    
25. OXNARD GR, Hu Y, Mileham KF, Husain H, et al
    Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib.
    JAMA Oncol. 2018 Aug 2. pii: 2694879. doi: 10.1001/jamaoncol.2018.2969.
    PubMed     Text format     Abstract available
    
    
    July 2018
26. GUIDA F, Sun N, Bantis LE, Muller DC, et al
    Assessment of Lung Cancer Risk on the Basis of a Biomarker Panel of Circulating Proteins.
    JAMA Oncol. 2018 Jul 12:e182078. doi: 10.1001/jamaoncol.2018.2078.
    PubMed     Text format     Abstract available
    
    
    June 2018
27. GANDARA DR, Riess JW, Lara PN Jr
    In Search of an Oncogene Driver for Squamous Lung Cancer.
    JAMA Oncol. 2018 Jun 14. pii: 2684629. doi: 10.1001/jamaoncol.2018.0774.
    PubMed     Text format    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: